Mosaic RASopathies

References

• Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim Biophys Acta 2002; 1602:23 - 45; PMID: 11960693
   PubMed Web of Science ®Google Scholar
• Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991; 349:117 - 27; http://dx.doi.org/10.1038/349117a0; PMID: 1898771
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295 - 308; http://dx.doi.org/10.1038/nrc2109; PMID: 17384584
   PubMed Web of Science ®Google Scholar
• Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19:230 - 6; http://dx.doi.org/10.1016/j.gde.2009.04.001; PMID: 19467855
   PubMed Web of Science ®Google Scholar
• Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005; 15:265 - 9; http://dx.doi.org/10.1016/j.gde.2005.03.004; PMID: 15917201
   PubMed Web of Science ®Google Scholar
• Eerola I, Boon LM, Mulliken JB, Burrows PE, Dompmartin A, Watanabe S, et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003; 73:1240 - 9; http://dx.doi.org/10.1086/379793; PMID: 14639529
   PubMed Web of Science ®Google Scholar
• Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 1987; 16:899 - 906; http://dx.doi.org/10.1016/S0190-9622(87)80249-9; PMID: 3033033
   PubMed Web of Science ®Google Scholar
• Hafner C, Toll A, Gantner S, Mauerer A, Lurkin I, Acquadro F, et al. Keratinocytic epidermal nevi are associated with mosaic RAS mutations. J Med Genet 2012; 49:249 - 53; http://dx.doi.org/10.1136/jmedgenet-2011-100637; PMID: 22499344
   PubMed Web of Science ®Google Scholar
• Happle R. Mosaicism in human skin. Understanding the patterns and mechanisms. Arch Dermatol 1993; 129:1460 - 70; http://dx.doi.org/10.1001/archderm.1993.01680320094012; PMID: 8239703
   PubMed Web of Science ®Google Scholar
• Happle R, Rogers M. Epidermal nevi. Adv Dermatol 2002; 18:175 - 201; PMID: 12528406
   PubMedGoogle Scholar
• Happle R. The group of epidermal nevus syndromes Part I. Well defined phenotypes. J Am Acad Dermatol 2010; 63:1 - 22, quiz 23-4; http://dx.doi.org/10.1016/j.jaad.2010.01.017; PMID: 20542174
   PubMed Web of Science ®Google Scholar
• Sugarman JL. Epidermal nevus syndromes. Semin Cutan Med Surg 2004; 23:145 - 57; http://dx.doi.org/10.1016/j.sder.2004.01.008; PMID: 15295924
   PubMed Web of Science ®Google Scholar
• Hafner C, López-Knowles E, Luis NM, Toll A, Baselga E, Fernández-Casado A, et al. Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci USA 2007; 104:13450 - 4; http://dx.doi.org/10.1073/pnas.0705218104; PMID: 17673550
   PubMed Web of Science ®Google Scholar
• Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, et al. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 2006; 116:2201 - 7; http://dx.doi.org/10.1172/JCI28163; PMID: 16841094
   PubMed Web of Science ®Google Scholar
• Hafner C, Di Martino E, Pitt E, Stempfl T, Tomlinson D, Hartmann A, et al. FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. Exp Cell Res 2010; 316:2008 - 16; http://dx.doi.org/10.1016/j.yexcr.2010.04.021; PMID: 20420824
   PubMed Web of Science ®Google Scholar
• di Martino E, L’Hôte CG, Kennedy W, Tomlinson DC, Knowles MA. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009; 28:4306 - 16; http://dx.doi.org/10.1038/onc.2009.280; PMID: 19749790
   PubMed Web of Science ®Google Scholar
• Vujevich JJ, Mancini AJ. The epidermal nevus syndromes: multisystem disorders. J Am Acad Dermatol 2004; 50:957 - 61; http://dx.doi.org/10.1016/S0190-9622(02)61547-6; PMID: 15153903
   PubMed Web of Science ®Google Scholar
• Bourdeaut F, Hérault A, Gentien D, Pierron G, Ballet S, Reynaud S, et al. Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. J Med Genet 2010; 47:859 - 62; http://dx.doi.org/10.1136/jmg.2009.075374; PMID: 20805368
   PubMed Web of Science ®Google Scholar
• Hafner C, Toll A, Real FX. HRAS mutation mosaicism causing urothelial cancer and epidermal nevus. N Engl J Med 2011; 365:1940 - 2; http://dx.doi.org/10.1056/NEJMc1109381; PMID: 22087699
   PubMed Web of Science ®Google Scholar
• Bygum A, Fagerberg CR, Clemmensen OJ, Fiebig B, Hafner C. Systemic epidermal nevus with involvement of the oral mucosa due to FGFR3 mutation. BMC Med Genet 2011; 12:79; http://dx.doi.org/10.1186/1471-2350-12-79; PMID: 21639936
   PubMed Web of Science ®Google Scholar
• Collin B, Taylor IB, Wilkie AO, Moss C. Fibroblast growth factor receptor 3 (FGFR3) mutation in a verrucous epidermal naevus associated with mild facial dysmorphism. Br J Dermatol 2007; 156:1353 - 6; http://dx.doi.org/10.1111/j.1365-2133.2007.07869.x; PMID: 17441958
   PubMed Web of Science ®Google Scholar
• García-Vargas A, Hafner C, Pérez-Rodríguez AG, Rodríguez-Rojas LX, González-Esqueda P, Stoehr R, et al. An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. Am J Med Genet A 2008; 146A:2275 - 9; http://dx.doi.org/10.1002/ajmg.a.32429; PMID: 18642369
   PubMed Web of Science ®Google Scholar
• Ousager LB, Bygum A, Hafner C. Identification of a novel S249C FGFR3 mutation in a keratinocytic epidermal naevus syndrome. Br J Dermatol 2012; 167:202 - 4; http://dx.doi.org/10.1111/j.1365-2133.2012.10812.x; PMID: 22229528
   PubMed Web of Science ®Google Scholar
• Moody MN, Landau JM, Goldberg LH. Nevus sebaceous revisited. Pediatr Dermatol 2012; 29:15 - 23; http://dx.doi.org/10.1111/j.1525-1470.2011.01562.x; PMID: 21995782
   PubMed Web of Science ®Google Scholar
• Groesser L, Herschberger E, Ruetten A, Ruivenkamp C, Lopriore E, Zutt M, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 2012; 44:783 - 7; http://dx.doi.org/10.1038/ng.2316; PMID: 22683711
   PubMed Web of Science ®Google Scholar
• Schimmelpenning GW. [Clinical contribution to symptomatology of phacomatosis]. Fortschr Geb Rontgenstr Nuklearmed 1957; 87:716 - 20; http://dx.doi.org/10.1055/s-0029-1213358; PMID: 13512450
   PubMedGoogle Scholar
• Davies D, Rogers M. Review of neurological manifestations in 196 patients with sebaceous naevi. Australas J Dermatol 2002; 43:20 - 3; http://dx.doi.org/10.1046/j.1440-0960.2002.00546.x; PMID: 11869203
   PubMedGoogle Scholar
• Rijntjes-Jacobs EG, Lopriore E, Steggerda SJ, Kant SG, Walther FJ. Discordance for Schimmelpenning-Feuerstein-Mims syndrome in monochorionic twins supports the concept of a postzygotic mutation. Am J Med Genet A 2010; 152A:2816 - 9; http://dx.doi.org/10.1002/ajmg.a.33635; PMID: 20949522
   PubMed Web of Science ®Google Scholar
• Zutt M, Strutz F, Happle R, Habenicht EM, Emmert S, Haenssle HA, et al. Schimmelpenning-Feuerstein-Mims syndrome with hypophosphatemic rickets. Dermatology 2003; 207:72 - 6; http://dx.doi.org/10.1159/000070948; PMID: 12835555
   PubMed Web of Science ®Google Scholar
• Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005; 37:1038 - 40; http://dx.doi.org/10.1038/ng1641; PMID: 16170316
   PubMed Web of Science ®Google Scholar
• Gripp KW, Lin AE. Costello syndrome: a Ras/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med 2012; 14:285 - 92; http://dx.doi.org/10.1038/gim.0b013e31822dd91f; PMID: 22261753
   PubMed Web of Science ®Google Scholar
• Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A 2006; 140:2163 - 9; http://dx.doi.org/10.1002/ajmg.a.31456; PMID: 16969868
   PubMed Web of Science ®Google Scholar
• Sol-Church K, Stabley DL, Demmer LA, Agbulos A, Lin AE, Smoot L, et al. Male-to-male transmission of Costello syndrome: G12S HRAS germline mutation inherited from a father with somatic mosaicism. Am J Med Genet A 2009; 149A:315 - 21; http://dx.doi.org/10.1002/ajmg.a.32639; PMID: 19206176
   PubMed Web of Science ®Google Scholar
• Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123:124 - 33; http://dx.doi.org/10.1542/peds.2007-3204; PMID: 19117870
   PubMed Web of Science ®Google Scholar
• Wiest V, Eisenbarth I, Schmegner C, Krone W, Assum G. Somatic NF1 mutation spectra in a family with neurofibromatosis type 1: toward a theory of genetic modifiers. Hum Mutat 2003; 22:423 - 7; http://dx.doi.org/10.1002/humu.10272; PMID: 14635100
   PubMed Web of Science ®Google Scholar
• Serra E, Ars E, Ravella A, Sánchez A, Puig S, Rosenbaum T, et al. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum Genet 2001; 108:416 - 29; http://dx.doi.org/10.1007/s004390100514; PMID: 11409870
   PubMed Web of Science ®Google Scholar
• Serra E, Rosenbaum T, Winner U, Aledo R, Ars E, Estivill X, et al. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum Mol Genet 2000; 9:3055 - 64; http://dx.doi.org/10.1093/hmg/9.20.3055; PMID: 11115850
   PubMed Web of Science ®Google Scholar
• Colman SD, Rasmussen SA, Ho VT, Abernathy CR, Wallace MR. Somatic mosaicism in a patient with neurofibromatosis type 1. Am J Hum Genet 1996; 58:484 - 90; PMID: 8644707
   PubMed Web of Science ®Google Scholar
• Vandenbroucke I, van Doorn R, Callens T, Cobben JM, Starink TM, Messiaen L. Genetic and clinical mosaicism in a patient with neurofibromatosis type 1. Hum Genet 2004; 114:284 - 90; http://dx.doi.org/10.1007/s00439-003-1047-9; PMID: 14605872
   PubMed Web of Science ®Google Scholar
• Redlick FP, Shaw JC. Segmental neurofibromatosis follows blaschko’s lines or dermatomes depending on the cell line affected: case report and literature review. J Cutan Med Surg 2004; 8:353 - 6; http://dx.doi.org/10.1007/s10227-005-0029-z; PMID: 15868313
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Mahmoudi A, Zeller J, Revuz J. More on the frequency of segmental neurofibromatosis. Arch Dermatol 1995; 131:1465; http://dx.doi.org/10.1001/archderm.1995.01690240131030; PMID: 7492147
   PubMed Web of Science ®Google Scholar
• Tinschert S, Naumann I, Stegmann E, Buske A, Kaufmann D, Thiel G, et al. Segmental neurofibromatosis is caused by somatic mutation of the neurofibromatosis type 1 (NF1) gene. Eur J Hum Genet 2000; 8:455 - 9; http://dx.doi.org/10.1038/sj.ejhg.5200493; PMID: 10878667
   PubMed Web of Science ®Google Scholar
• Writzl K, Hoovers J, Sistermans EA, Hennekam RC. LEOPARD syndrome with partly normal skin and sex chromosome mosaicism. Am J Med Genet A 2007; 143A:2612 - 5; http://dx.doi.org/10.1002/ajmg.a.31991; PMID: 17935252
   PubMed Web of Science ®Google Scholar
• Bernard-Pierrot I, Brams A, Dunois-Lardé C, Caillault A, Diez de Medina SG, Cappellen D, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006; 27:740 - 7; http://dx.doi.org/10.1093/carcin/bgi290; PMID: 16338952
   PubMed Web of Science ®Google Scholar
• Hernández S, Toll A, Baselga E, Ribé A, Azua-Romeo J, Pujol RM, et al. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol 2007; 127:1664 - 6; PMID: 17255960
   PubMed Web of Science ®Google Scholar
• Hafner C, Vogt T, Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle 2006; 5:2723 - 8; http://dx.doi.org/10.4161/cc.5.23.3509; PMID: 17172848
   PubMed Web of Science ®Google Scholar
• Hafner C, Hartmann A, Real FX, Hofstaedter F, Landthaler M, Vogt T. Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses. J Invest Dermatol 2007; 127:1883 - 5; http://dx.doi.org/10.1038/sj.jid.5700804; PMID: 17392824
   PubMed Web of Science ®Google Scholar
• Hafner C, Toll A, Fernández-Casado A, Earl J, Marqués M, Acquadro F, et al. Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors. Proc Natl Acad Sci USA 2010; 107:20780 - 5; http://dx.doi.org/10.1073/pnas.1008365107; PMID: 21078999
   PubMed Web of Science ®Google Scholar
• Hafner C, van Oers JM, Hartmann A, Landthaler M, Stoehr R, Blaszyk H, et al. High frequency of FGFR3 mutations in adenoid seborrheic keratoses. J Invest Dermatol 2006; 126:2404 - 7; http://dx.doi.org/10.1038/sj.jid.5700422; PMID: 16778799
   PubMed Web of Science ®Google Scholar
• Siegel DH, Mann JA, Krol AL, Rauen KA. Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development. Br J Dermatol 2012; 166:601 - 7; http://dx.doi.org/10.1111/j.1365-2133.2011.10744.x; PMID: 22098123
   PubMed Web of Science ®Google Scholar
• Downward J. Signal transduction. Prelude to an anniversary for the RAS oncogene. Science 2006; 314:433 - 4; http://dx.doi.org/10.1126/science.1134727; PMID: 17053139
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949 - 54; http://dx.doi.org/10.1038/nature00766; PMID: 12068308
   PubMed Web of Science ®Google Scholar
• Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33:19 - 20; http://dx.doi.org/10.1038/ng1054; PMID: 12447372
   PubMed Web of Science ®Google Scholar
• Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011; 157:83 - 9; http://dx.doi.org/10.1002/ajmg.c.30300; PMID: 21500339
   PubMed Web of Science ®Google Scholar
• Side L, Taylor B, Cayouette M, Conner E, Thompson P, Luce M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997; 336:1713 - 20; http://dx.doi.org/10.1056/NEJM199706123362404; PMID: 9180088
   PubMed Web of Science ®Google Scholar
• Leroy K, Dumas V, Martin-Garcia N, Falzone MC, Voisin MC, Wechsler J, et al. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 2001; 137:908 - 13; PMID: 11453810
   PubMed Web of Science ®Google Scholar
• Thiagalingam S, Flaherty M, Billson F, North K. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004; 111:568 - 77; http://dx.doi.org/10.1016/j.ophtha.2003.06.008; PMID: 15019338
   PubMed Web of Science ®Google Scholar
• Bausch B, Borozdin W, Neumann HP, European-American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. N Engl J Med 2006; 354:2729 - 31; http://dx.doi.org/10.1056/NEJMc066006; PMID: 16790714
   PubMed Web of Science ®Google Scholar
• Martinelli S, McDowell HP, Vigne SD, Kokai G, Uccini S, Tartaglia M, et al. RAS signaling dysregulation in human embryonal Rhabdomyosarcoma. Genes Chromosomes Cancer 2009; 48:975 - 82; http://dx.doi.org/10.1002/gcc.20702; PMID: 19681119
   PubMed Web of Science ®Google Scholar
• Flosadóttir E, Bjarnason B. A non-epidermolytic epidermal naevus of a soft, papillomatous type with transitional cell cancer of the bladder: a case report and a review of non-cutaneous cancers associated with the epidermal naevi. Acta Derm Venereol 2008; 88:173 - 5; http://dx.doi.org/10.2340/00015555-0365; PMID: 18311453
   PubMed Web of Science ®Google Scholar
• Vidaurri-de la Cruz H, Tamayo-Sánchez L, Durán-McKinster C, de la Luz Orozco-Covarrubias M, Ruiz-Maldonado R. Epidermal nevus syndromes: clinical findings in 35 patients. Pediatr Dermatol 2004; 21:432 - 9; http://dx.doi.org/10.1111/j.0736-8046.2004.21402.x; PMID: 15283784
   PubMed Web of Science ®Google Scholar
• García de Jalón A, Azúa-Romeo J, Trivez MA, Pascual D, Blas M, Rioja LA. Epidermal naevus syndrome (Solomon’s syndrome) associated with bladder cancer in a 20-year-old female. Scand J Urol Nephrol 2004; 38:85 - 7; http://dx.doi.org/10.1080/00365590310017316; PMID: 15204433
   PubMed Web of Science ®Google Scholar
• Rongioletti F, Rebora A. Epidermal nevus with transitional cell carcinomas of the urinary tract. J Am Acad Dermatol 1991; 25:856 - 8; http://dx.doi.org/10.1016/S0190-9622(08)80987-5; PMID: 1802914
   PubMed Web of Science ®Google Scholar
• Rosenthal D, Fretzin DF. Epidermal nevus syndrome: report of association with transitional cell carcinoma of the bladder. Pediatr Dermatol 1986; 3:455 - 8; http://dx.doi.org/10.1111/j.1525-1470.1986.tb00650.x; PMID: 3562359
   PubMedGoogle Scholar
• Ball EA, Hussain M, Moss AL. Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol 2005; 30:259 - 60; http://dx.doi.org/10.1111/j.1365-2230.2005.01744.x; PMID: 15807685
   PubMed Web of Science ®Google Scholar
• Chou CY, Chen WY, Wang KH, Chen TJ. Carcinosarcoma derived from nevus sebaceus. J Clin Oncol 2011; 29:e719 - 21; http://dx.doi.org/10.1200/JCO.2011.35.8093; PMID: 21788565
   PubMedGoogle Scholar
• Izumi M, Tang X, Chiu CS, Nagai T, Matsubayashi J, Iwaya K, et al. Ten cases of sebaceous carcinoma arising in nevus sebaceus. J Dermatol 2008; 35:704 - 11; http://dx.doi.org/10.1111/j.1346-8138.2008.00550.x; PMID: 19120764
   PubMed Web of Science ®Google Scholar
• Mauerer A, Herschberger E, Dietmaier W, Landthaler M, Hafner C. Low incidence of EGFR and HRAS mutations in cutaneous squamous cell carcinomas of a German cohort. Exp Dermatol 2011; 20:848 - 50; http://dx.doi.org/10.1111/j.1600-0625.2011.01334.x; PMID: 21771097
   PubMed Web of Science ®Google Scholar
• Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30:316 - 21; http://dx.doi.org/10.1200/JCO.2011.36.7680; PMID: 22067401
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366:207 - 15; http://dx.doi.org/10.1056/NEJMoa1105358; PMID: 22256804
   PubMed Web of Science ®Google Scholar
• Hafner C, Klein A, Landthaler M, Vogt T. Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis. Dermatology 2009; 218:278 - 81; http://dx.doi.org/10.1159/000189209; PMID: 19122450
   PubMed Web of Science ®Google Scholar
• Tavormina PL, Shiang R, Thompson LM, Zhu YZ, Wilkin DJ, Lachman RS, et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nat Genet 1995; 9:321 - 8; http://dx.doi.org/10.1038/ng0395-321; PMID: 7773297
   PubMed Web of Science ®Google Scholar